- Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis2023 | Publication without faculty affiliation
- DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS2018 | First Faculty of Medicine
- Sparsentan – nová možnost léčby pacientů s fokálně segmentální glomerulosklerózou?2023 | First Faculty of Medicine
- Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial2023 | First Faculty of Medicine
- Sparsentan. Dual angiotensin II AT1 receptor blocker and endothelin ETA receptor antagonist, Treatment of focal segmental glomerulosclerosis, Treatment of IgA nephropathy2020 | First Faculty of Medicine
- Novinky v léčbě Alportova syndromu2023 | First Faculty of Medicine